ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) Impresses with Pipeline

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) shares traded at over twice their normal volumes and ended the day up over 6% at $1.74. CTRV shares have generally been on the upswing. Although down just -1.21% for the week, CTRV shares are up 9.4% for the month, up 20.74% for the quarter, up 35.83% YTD, and up 9.4% for the year.

Edison, NJ-based ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) is a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). ContraVir is developing two novel anti-HBV compounds with complementary mechanisms of action: Tenofovir Exalidex (TXL™), (formerly CMX157), a highly potent analog of the successful antiviral drug tenofovir currently in a Phase 2a clinical trial in HBV patients. John Sullivan-Bolyai, MD, MPH, Chief Medical Officer of ContraVir, will give an oral presentation at the 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) to be held February 15-19, 2017, at the Shanghai International Convention Center. The presentation will highlight Phase 2a data for Tenofovir Exalidex (TXL™) – formerly CMX157.

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) is developing CRV431, a next generation cyclophilin inhibitor with a unique structure that increases its potency and selective index against HBV. In January, Canada’s National Research Council awarded ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) $297,875 towards the development of CRV431.

ContraVir is also developing ValnivudineTM (formerly FV-100), an orally available nucleoside analogue prodrug for the treatment of herpes zoster, or shingles, in a Phase 3 clinical trial. In addition to direct antiviral activity, Valnivudine previously demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study.

Two research firms follow ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV). Both rate CTRV shares as a “Strong Buy” with a consensus price target of $4.50 – about 250% higher than current price levels.

3/28/2017
Ticker Symbol IMMY
Last Price a/o 4:00 PM EST  $                      1.76
Average Volume                    500,950
Market Cap (mlns)  $                  102.36
Sales (mlns) $0.00
Shares Outstanding (mlns) 62.8
Share Float (mlns) 58.28
Shortable Yes
Optionable No
Inside Ownership 0.10%
Short Float 4.85%
Short Interest Ratio 5.65
Quarterly Return 20.74%
YTD Return 35.83%
Year Return 9.40%

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Author: Marcus Anderson

Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Leave a Reply

Your email address will not be published. Required fields are marked *